How to Reconstitute Egrifta (Tesamorelin) for Travel and Transport Without Losing Potency

What Is Egrifta (Tesamorelin) and Why Reconstitution Technique Matters

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The FDA approved Egrifta SV (tesamorelin 2 mg) for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Off-label, clinicians prescribe it for metabolic and body-composition goals in women with conditions such as PCOS-related visceral adiposity, age-related GH decline in post-menopause, and sarcopenic obesity.

Potency is fragile. Tesamorelin is a 44-amino-acid peptide; even brief exposure to heat, light, or the wrong diluent causes aggregation and loss of biological activity. A woman injecting a degraded solution gets no clinical effect and assumes the drug has failed her. Correct reconstitution is therefore not a minor procedural footnote. It is the difference between a working therapy and an expensive placebo.

The sections below walk through every step at MD/PharmD-level detail, with specific guidance for travel, because that is where cold-chain failures most commonly happen.

The Egrifta SV Reconstitution Protocol, Step by Step

The manufacturer's prescribing information specifies an exact technique for Egrifta SV per the FDA-approved labeling. Follow it precisely; improvising diluent or volume changes the concentration and your effective dose.

What You Need Before You Start

Gather these supplies before touching the vial:

• One 2 mg tesamorelin lyophilized powder vial (Egrifta SV)
• One 10 mL vial of sterile water for injection (SWFI) supplied with the kit, or bacteriostatic water for injection (BWFI) if you are managing multi-dose vials off-label
• One 1 mL or 3 mL syringe with a draw needle (18-21 gauge) for pulling diluent
• One insulin syringe (typically 0.5 mL or 1 mL, 28-31 gauge, 6-8 mm needle) for the subcutaneous injection
• 70% isopropyl alcohol swabs
• A clean, flat, well-lit surface

Do not use saline (0.9% NaCl) as your diluent. Saline is not listed in the approved labeling and has been associated with peptide aggregation in lyophilized GH-family peptides.

Reconstitution: The Exact Steps

1. Wash hands for 20 seconds. Let them dry fully.
2. Swab the rubber septum of both vials with a fresh alcohol swab. Let air-dry for 10 seconds. Do not blow on them.
3. Draw 2.2 mL of SWFI (or BWFI if using multi-dose protocol) into the draw syringe.
4. Inject the diluent slowly down the inner wall of the powder vial. Do not aim the stream directly at the powder cake; direct force causes foaming and peptide shearing.
5. Roll the vial gently between your palms for 30 seconds. Never shake it. Shaking introduces air bubbles and denatures the peptide.
6. Inspect the solution. It should be clear and colorless. Discard it if you see particulates, cloudiness, or a yellow tint.
7. Draw the reconstituted solution into your insulin syringe immediately, or store it as described below.

The final concentration after adding 2.2 mL to 2 mg tesamorelin is approximately 0.91 mg/mL.

Insulin Syringe Selection and Dose Calculation

A standard 2 mg daily dose at 0.91 mg/mL requires approximately 2.2 mL total volume, which exceeds a 1 mL insulin syringe. Most clinicians draw 1 mL for the first injection and 1.2 mL for the second, but this split-dose approach should only be used if your prescriber has specified it. For the standard single-dose kit, you inject the full 2.2 mL in a single subcutaneous session using a larger-barrel insulin syringe or a 3 mL low-dead-volume syringe with a fine needle.

If you are using a U-100 insulin syringe (which reads in units, not mL), remember: 100 units = 1 mL. So 2.2 mL = 220 units on a U-100 syringe. A standard 1 mL insulin syringe only holds 100 units. Use a 3 mL syringe with an attached or changeable fine needle, or two separate 1 mL syringes pre-drawn and stored per your pharmacist's cold-chain instructions.

WomanRx Dose Verification Framework for Tesamorelin Injections:

| Step | Action | Why It Matters | |---|---|---| | Confirm vial mg | Read label: 1 mg or 2 mg? | Egrifta and Egrifta SV differ | | Confirm diluent volume | 2.2 mL for Egrifta SV 2 mg | Changes mg/mL calculation | | Confirm syringe calibration | mL or units? | U-100 insulin syringes read in units | | Calculate draw volume | Dose (mg) / concentration (mg/mL) | Double-check with pharmacist | | Inspect before injecting | Clear, colorless, no particles | Degraded solution = no effect |

Bacteriostatic Water vs. Sterile Water: Which Should You Use?

For the single-dose Egrifta SV kit, the manufacturer provides sterile water for injection and requires you to use the solution within 24 hours. This is because SWFI contains no preservative. Bacteria can grow in an open SWFI vial within hours at room temperature.

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and extends the usable window of a reconstituted vial. Off-label compounded tesamorelin preparations often specify BWFI precisely for this reason. USP General Chapter <797> governs compounded sterile preparations and sets beyond-use dating rules that compounding pharmacies must follow; ask your pharmacy for the specific beyond-use date they assign to your preparation, because it will vary by their sterility testing data.

Key rule: If your kit says sterile water, use it and discard after 24 hours. If your compounding pharmacy says BWFI, follow their labeled beyond-use date. Never mix the two assumptions.

Why 24 Hours Matters More Than You Think

Peptide stability is not just about microbial contamination. Tesamorelin contains a trans-3-hexenoic acid modification at the N-terminus that makes it more resistant to degradation than native GHRH, but it is still subject to hydrolysis and oxidation once in solution. Studies on GHRH-analogue peptides in solution show significant potency loss at room temperature within 6-12 hours and accelerated degradation above 25 °C.

Refrigerated (2-8 °C) storage slows both microbial growth and chemical degradation. Frozen storage (<0 °C) does not extend usability for reconstituted solutions. Ice crystal formation physically shears peptide secondary structure. A reconstituted vial left in a hotel minibar freezer is a ruined vial.

Traveling With Tesamorelin: A Practical Cold-Chain Guide

Traveling with injectable peptides is manageable if you plan ahead. The single point of failure for most patients is the gap between leaving home refrigeration and reaching destination refrigeration. That window is where potency dies.

Before You Leave Home

• Reconstitute only what you will use within 24 hours if you are using SWFI. If you are traveling longer, bring lyophilized (powder) vials and reconstitute at your destination.
• Pack extra SWFI or BWFI vials and syringes. Airlines lose luggage. Pharmacies in foreign countries may not stock the exact diluent.
• Get a letter of medical necessity from your prescriber on letterhead. TSA and international customs agents sometimes flag injectable medications. The letter should state the drug name, your diagnosis, and that the medication requires refrigeration.
• TSA allows medically necessary liquids and gels in excess of 3.4 oz when properly declared; declare at the checkpoint.

Insulated Medical Coolers: What Actually Works

A standard picnic cooler is not adequate. You need a medical-grade insulated case that maintains 2-8 °C for at least 24-36 hours without active refrigeration. Products tested in pharmaceutical cold-chain research show that phase-change material (PCM) packs maintain tighter temperature ranges than standard gel ice packs, which can drop below 0 °C and freeze your vials on contact.

Practical rules for your cooler:

• Pre-chill the cooler for 2 hours before packing.
• Wrap vials in a small cloth or bubble wrap so they are never in direct contact with the cooling element.
• Use a temperature data logger (small, inexpensive, available online) if you are traveling for more than 48 hours. This tells you whether the cold chain held.
• If a vial reaches above 25 °C for more than 4 hours, treat it as compromised and discard.

At Your Destination

Locate refrigeration within 4 hours of arrival. Hotels always have a mini-fridge; call ahead and confirm it is a genuine refrigerator (temperature 2-8 °C), not a wine cooler set to 14 °C. If your room does not have one, the front desk almost always has a guest refrigerator. Do not be shy about asking. Your medication requires it.

Set the fridge to its coldest setting that does not freeze, and use a small thermometer to verify. Reconstituted tesamorelin sitting at 10-14 °C in a too-warm hotel mini-fridge degrades faster than the 24-hour window assumes.

Women-Specific Physiology: How Sex Hormones Affect Tesamorelin Response

Most published tesamorelin efficacy data comes from the AXIS 1 and AXIS 2 trials, which enrolled adults with HIV-associated lipodystrophy. In AXIS 1, tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by 18% vs. 2% with placebo at 26 weeks. Women were represented in these trials but were a minority, and sex-stratified efficacy data is limited. That is an evidence gap you deserve to know about.

Estrogen, GH Pulsatility, and Why Women May Need a Different Lens

Estrogen directly modulates GH secretion and IGF-1 synthesis. Women produce GH in a more frequent, lower-amplitude pulsatile pattern compared to men, and post-menopausal women have significantly lower IGF-1 levels than age-matched men, partly because declining estrogen reduces hepatic IGF-1 production. Oral estrogen (including combined oral contraceptives) suppresses hepatic IGF-1 synthesis by first-pass effect, which can blunt the IGF-1 response to tesamorelin. Transdermal estrogen does not carry this first-pass burden and is associated with better IGF-1 preservation.

If you are on oral estrogen-containing contraception or oral menopausal hormone therapy, tell your prescriber before starting tesamorelin. Your IGF-1 response may be attenuated, and your clinician may want to track IGF-1 levels more closely or consider switching you to a transdermal estrogen formulation.

Life-Stage Considerations

Reproductive years (menstruating women): GH pulsatility and IGF-1 fluctuate across the menstrual cycle. Estrogen peaks in the late follicular phase are associated with transient increases in GH sensitivity. There are no data on whether timing tesamorelin injections relative to cycle phase improves outcomes; this is an open research question.

Perimenopause: Erratic estrogen levels make IGF-1 interpretation difficult. Women in perimenopause may see variable responses to tesamorelin from month to month that track with their hormonal fluctuations rather than medication failure.

Post-menopause: Lower baseline GH secretion and IGF-1 may mean a longer time to see visceral fat reduction. A 2003 study in post-menopausal women receiving GHRH-analogue therapy found IGF-1 responses roughly half those seen in men of similar age, supporting the need for individualized monitoring rather than fixed dose assumptions.

PCOS: Women with PCOS often have altered GH secretion patterns, with blunted GH pulses and elevated insulin-like growth factor binding protein-1 (IGFBP-1). How tesamorelin interacts with this pattern is not well-studied. Clinicians should monitor fasting glucose and IGF-1 closely, given the insulin-resistance context of PCOS.

Pregnancy, Lactation, and Contraception: Required Reading

Egrifta is FDA Pregnancy Category X. Do not use tesamorelin if you are pregnant, planning to become pregnant, or not using reliable contraception.

The Egrifta SV prescribing information states that animal studies showed fetal harm and there are no adequate human pregnancy data. Animal reproductive toxicology studies with GHRH analogues demonstrated embryotoxicity at clinically relevant exposures. The theoretical mechanism for harm is disruption of fetal GH-IGF-1 axis development, which is active throughout gestation.

Contraception Requirement

If you are of reproductive potential and using tesamorelin, you must use effective contraception. Discuss your options with your prescriber. ACOG recommends long-acting reversible contraceptives (LARCs) as highly effective first-line options for women who need reliable pregnancy prevention during teratogenic drug therapy.

Lactation

There are no human data on whether tesamorelin transfers into breast milk. Tesamorelin is a large peptide (molecular weight approximately 5,135 Da); large peptides are generally poorly absorbed from the neonatal GI tract even if present in milk. However, the absence of safety data means the FDA labeling advises against use during breastfeeding. The decision to stop breastfeeding or stop tesamorelin should account for the clinical importance of the drug to the mother, and should be made with your prescriber and, if possible, a lactation medicine specialist.

Who This Is Right For and Who Should Pause

Tesamorelin is not appropriate for every woman asking about it. The following framework is meant to help you have a more specific conversation with your clinician, not to replace that conversation.

Women for whom tesamorelin may be appropriate:

• Women with confirmed HIV-associated lipodystrophy and excess VAT (FDA-approved indication)
• Post-menopausal women with age-related GH decline, sarcopenia, and visceral adiposity, evaluated by a clinician comfortable with off-label peptide use
• Women with documented low IGF-1 who have not responded adequately to lifestyle interventions

Women who should not use tesamorelin or should use it only with close monitoring:

• Any woman who is pregnant, trying to conceive, or not using reliable contraception (absolute contraindication)
• Women with active malignancy or a history of malignancy (GH axis stimulation is a theoretical risk)
• Women with diabetes or pre-diabetes: tesamorelin can cause glucose intolerance; the AXIS trials showed a small but measurable increase in HbA1c at 26 weeks
• Women with carpal tunnel syndrome (tesamorelin increases GH, which can worsen fluid retention and nerve compression)
• Women on oral estrogen therapy without transdermal alternatives discussed: attenuated IGF-1 response may mean reduced benefit

Injection Site Rotation and Subcutaneous Technique for Women

The recommended injection sites are the abdomen (at least 2 inches from the navel), the front of the thigh, and the upper arm. For women with higher subcutaneous fat stores in specific areas, site selection affects both comfort and absorption.

Subcutaneous absorption of peptide drugs varies by site, with abdominal sites generally providing the most consistent absorption kinetics. Rotate within and across sites to prevent lipodystrophy (ironic but real: repeated injections at the same site cause subcutaneous atrophy or hypertrophy that impairs drug absorption).

Inject at a 45-90 degree angle depending on subcutaneous tissue depth. Women with less subcutaneous abdominal fat should use a 45-degree angle with a shorter needle to avoid intramuscular injection. Women with more subcutaneous fat can use a 90-degree angle with a standard insulin needle length. Pinching the skin before injection reduces the risk of hitting muscle.

Inject at room temperature. Drawing the syringe from the refrigerator and injecting immediately can cause localized stinging from the cold solution; let the drawn syringe sit for 5 minutes at room temperature before injecting.

Common Reconstitution Errors and How to Avoid Them

USP General Chapter <797> establishes standards for compounded sterile preparations and defines beyond-use dating, but the principles apply equally to patient-administered reconstitution at home:

| Error | Consequence | Prevention | |---|---|---| | Shaking the vial vigorously | Foaming, peptide denaturation | Roll gently only | | Using saline as diluent | Aggregation, potency loss | Use SWFI or BWFI only | | Direct stream onto powder cake | Foaming, incomplete dissolution | Aim at inner vial wall | | Storing reconstituted vial at room temperature overnight | Microbial growth, hydrolysis | Refrigerate immediately; discard in 24 h if using SWFI | | Freezing reconstituted solution | Ice crystal shearing of peptide | Never freeze after reconstitution | | Reusing needles | Core contamination of vial, injection pain | One needle per draw | | Mixing two vials into one | Compounding error; no sterility guarantee | Never pool vials |

Monitoring: What to Track and When

Your prescriber should check IGF-1 levels at baseline, at 8-12 weeks, and at 6 months. IGF-1 should increase but should not exceed the upper limit of the age- and sex-adjusted normal range. Supraphysiologic IGF-1 is a signal to reduce dose or discontinue.

Women with PCOS or pre-diabetes should have fasting glucose and HbA1c checked at baseline and at 3-month intervals. The AXIS 1 trial reported that tesamorelin increased fasting glucose by approximately 3 mg/dL vs. Placebo at 26 weeks, a modest but real signal that requires monitoring.

A DXA scan at baseline and at 6 months provides objective data on visceral fat and lean mass changes. Without objective measurement, it is difficult to know whether the drug is working or whether you are responding adequately to justify continued use.